Colorectal cancer: Chemopreventive role of curcumin and resveratrol

Nutrition and Cancer

Volumn 62, Issue 7, 2010, Pages 958-967

  Patel, Vaishali B ^a   Misra, Sabeena ^a   Patel, Bhaumik B ^b   Majumdar, Adhip P N ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CISPLATIN; CURCUMIN; CURCUMIN SULPHATE; CYCLOOXYGENASE 2; DOXORUBICIN; DRUG METABOLITE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; GELATINASE B; GEMCITABINE; HEXAHYDROCURCUMIN; HEXAHYDROCURCUMINOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; PIPERINE; QUERCETIN; RESVERATROL; SULINDAC; TETRAHYDROCURCUMIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHEMICAL COMPOSITION; CHEMOPROPHYLAXIS; CHEMOSENSITIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG ISOLATION; DRUG METABOLISM; DRUG SAFETY; DRUG TISSUE LEVEL; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CURCUMIN; HUMANS; STILBENES;

EID: 77957976610     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.510259     Document Type: Review

References (110)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2006. CA Cancer J Clin 56, 106-130, 2006.
2. Negri E, Franceschi S, Parpinel M, and La Vecchia C: Fiber intake and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 7, 667-671, 1998. (Pubitemid 28374596)
3. Burt RW, DiSario JA, and Cannon-Albright L: Genetics of colon cancer: impact of inheritance on colon cancer risk. Annu Rev Med 46, 371-379, 1995.
4. Ponz de Leon M, Sassatelli R, Benatti P, and Roncucci L: Identification of hereditary nonpolyposis colorectal cancer in the general population: the 6-year experience of a population-based registry. Cancer 71, 3493-3501, 1993.
5. Fearon ER and Vogelstein B: Agenetic model for colorectal tumorigenesis. Cell 61, 759-767, 1990.
6. Lin DL, Whitney MC, Yao Z, and Keller ET: Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res 7, 1773-1781, 2001.
7. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, et al.: Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1, 229-233, 1992.
8. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 319, 525-532, 1988.
9. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, et al.: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418, 934, 2002.
10. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, et al.: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38, 787-793, 2006.
11. Takayama T, Ohi M, Hayashi T, Miyanishi K, Nobuoka A, et al.: Analysis of K-ras, APC, and beta-catenin in aberrant crypt foci in sporadic adenoma, cancer, and familial adenomatous polyposis. Gastroenterology 1213, 599-611, 2001.
12. Riggins GJ, Thiagalingam S, Rozenblum E, Weinstein CL, Kern SE, et al.: Mad-related genes in the human. Nat Genet 13, 347-349, 1996.
13. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220, 1997.
14. Bemis DL, Katz AE, and Buttyan R: Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 15, 1191-1200, 2006.
15. Aziz MH, Kumar R, and N Ahmad: Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23, 17-28, 2003.
16. Lodha R and Bagga A. Traditional Indian systems of medicine. Ann Acad Med Singapore 29, 37-41, 2000.
17. Araujo CC and Leon LL: Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz 96, 723-728, 2001.
18. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, et al.: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370-8377, 2001.
19. Kiso Y, Suzuki Y, Watanabe N, Oshima Y, and Hikino H: Antihepatotoxic principles of Curcuma longa rhizomes. Planta Med 49, 185-187, 1983. (Pubitemid 14220766)
20. Venkatesan N: Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124, 425-427, 1998.
21. Srinivasan M: Effect of curcumin on blood sugar as seen in a diabetic subject. Indian J Med Sci 26, 269-270, 1972.
22. Deodhar SD, Sethi R, and Srimal RC: Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Ind J Med Res 71, 632-634, 1980.
23. Rao CV, Rivenson A, Simi B, and Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 55, 259-266, 1995.
24. Ravindranath V and Chandrasekhara N: Absorption and tissue distribution of curcumin in rats. Toxicology 16, 259-265, 1980.
25. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895-2900, 2001.
26. Daube FV: Uber curcumin, den farbstoff der Curcumawurzel. Ber Deutsch Chem Ges 3, 609-613, 1870.
27. Tonnesen HH and Karlsen J: Studies on curcumin and curcuminoids: VI. kinetics of curcumin degradation in aqueous solution. Z Lebensm Unters Forsch 180, 402-404, 1985.
28. Srinivasan KR: The coloring matter in Turmeric. Curr Sci 21, 311-312, 1952.
29. Sharma RA, Gescher AJ, and Steward WP: Curcumin: the story so far. Eur J Cancer 41, 1955-1968, 2005.
30. Pan MH, Huang TM, and Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486-494, 1999.
31. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, et al.: Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 90, 1011-1015, 2004.
32. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, et al.: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 1, 120-125, 2005.
33. Ireson C, Orr S, Jones DJ, Verschoyle R, Lim CK, et al.: Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res 61, 1058-1064, 2001.
34. Li L, Braiteh FS, and Kurzrock R: Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104, 1322-1331, 2005.
35. Bisht S, Feldmann G, Soni S, Ravi R, Karikar C, et al.: Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnol 5, 3, 2007.
36. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353-356, 1998.
37. H Chen H, Zhang ZS, Zhang YL, and Zhou DY: Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cell lines. Anticancer Res 19, 3675-3680, 1999.
38. Simon A, Allais DP, Duroux JL, Basly JP, Durand-Fontanier S, et al.: Inhibitory effect of curcuminoids on MCF-7 cell proliferation and structure-activity relationships. Cancer Lett 129, 111-116, 1998.
39. Shishodia S, Amin HM, Lai R, and Aggarwal BB: Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70, 700-713, 2005.
40. Bharti AC, Donato N, Singh S, and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factorkappa B and Ikappa Balpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101, 1053-1062, 2003.
41. Scott DW and Loo G: Curcumin-induced GADD153 gene up-regulation in human colon cancer cells. Carcinogenesis 25, 2155-2164, 2004.
42. Collett GP and Campbell FC: Curcumin induces c-jun N-terminal kinasedependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis 25, 2183-2189, 2004.
43. Singh AK, Sidhu GS, Deepa T, and Maheshwari RK: Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 107, 109-115, 1996.
44. Khafif A, Hurst R, Kyker K, Fliss DM, Gil Z, et al.: Curcumin: anew radiosensitizer of squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132, 317-321, 2005.
45. Jiang MC, Yang-Yen HF, Yen JJ, and Lin JK: Curcumin induces apoptosis in immortalized NIH 3T3 and malignant cancer cell lines. Nutr Cancer 26, 111-120, 1996.
46. Aggarwal S, Ichikawa H, Takada Y, Sandur SK, Shishodia S, et al.: Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of IkappaBalpha kinase and Akt activation. Mol Pharmacol 69, 195-206, 2006.
47. Tsvetkov P, Asher G, Reiss V, Shaul Y, Sachs L, et al.: Inhibition of NAD (P) H : quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. Proc Natl Acad Sci USA 102, 5535-5540, 2005.
48. Han SS, Chung ST, Robertson DA, Ranjan D, and Bondada S: Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53. Clin Immunol 93, 152-161, 1999.
49. Chen AP and Xu J: Activation of PPAR gamma by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol 288, G447-G456, 2005.
50. Xu J, Fu Y, and Chen A: Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285, G20-G30, 2003.
51. Gururaj AE, Belakavadi M, Venkatesh DA, Marmé D, and Salimath BP: Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun 297, 934-942, 2002.
52. Yang X, Thomas DP, Zhang X, Culver BW, Alexander BM, et al.: Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 26, 85-90, 2006.
53. Thapliyal R and Maru GB: Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol 39, 541-547, 2001.
54. Rinaldi AL, Morse MA, Fields HW, Rothas DA, Pei P, et al.: Curicumin activates the aryl hydrocarbon receptor yet significantly inhibits (-) - benzo (a) pyrene-7R-trans-7, 8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. Cancer Res 62, 5451-5456, 2002.
55. Sharma RA, Ireson CR, Verschoyle RD, Hill KA, Williams ML, et al.: Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels. Clin Cancer Res 7, 1452-1458, 2001.
56. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, et al.: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18, 6013-6020, 1999.
57. Lev-Ari S, Strier L, Kazanov D, Madar-Shapiro L, Dvory-Sobol H, et al.: Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11, 6738-6744, 2005.
58. Korutla L and Kumar R: Inhibitory effect of curcuminon epidermal growth factor receptor kinase activity in A431 cells. Biochim Biophys Acta 1224, 597-600, 2004.
59. Korutla L, Cheung JY, Mendelsohn J, and Kumar R: Inhibition of ligandinduced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis 16, 1741-1745, 1995.
60. Leu TH and Maa MC: The molecular mechanisms for the antitumorigenic effect of curcumin. Curr Med Chem Anticancer Agents 2, 357-370, 2002.
61. Tikhomirov O and Carpenter G: Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63, 39-43, 2003.
62. Chen A, Xu J, and Johnson AC: Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 25, 278-287, 2006.
63. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270, 24995-25000, 1995.
64. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, et al.: Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163, 3474-3483, 1999.
65. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, et al.: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signaling complex. Oncogene 18, 6013-6020, 1999.
66. Kumar A, Dhawan S, Hardegen NJ, and Aggarwal BB: Curcumin (diferuloylmethane) inhibitionoftumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB activation. Biochem Pharmacol 55, 775-783, 1998.
67. Shishodia S, Potdar P, Gairola CG, and Aggarwal BB: Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24, 1269-1279, 2003.
68. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, et al.: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490-7498, 2005.
69. Ramachandran C, Fonseca HB, Jhabvala P, Escalon EA, and Melnick SJ: Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 184, 1-6, 2002.
70. Mukherjee Nee, Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, et al.: Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol Cell Biochem 297, 31-39, 2007.
71. Chakraborty S, Ghosh U, Bhattacharyya NP, Bhattacharya RK, and Roy M: Inhibition of telomerase activity and induction of apoptosis by curcumin in K-562 cells. Mutat Res 596, 81-90, 2006.
72. Karin M, Liu Z, and Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 9, 240-244, 1997.
73. Xia Y, Makris C, Su B, Li E, Yang J, and Nemerow GR, et al.: MEK kinase 1 is critically required for c-Jun. N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A 97, 5243-5248, 2000.
74. Chen YR and Tan TH: Inhibition of the c-Jun. N-terminal kinase (JNK) signaling pathway by curcumin. Oncogene 17, 173-178, 1998.
75. Kakar SS and Roy D: Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin. Cancer Lett 87, 85-89, 1994.
76. Bierhaus A, Zhang Y, Quehenberger P, Luther T, Haase M, et al.: The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 77, 772-782, 1997.
77. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, and Ahmed MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23, 1599-1607, 2004.
78. Limtrakul P, Anuchapreeda S, and Buddhasukh D: Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer 4, 13, 2004.
79. Li L, Ahmed B, Mehta K, and Kurzrock R: Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther 6, 1276-1282, 2007.
80. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, et al.: Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 224, 53-65, 2005.
81. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, et al.: Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63, 1709-1716, 2002.
82. Reddy S, Rishi AK, Xu H, Levi E, Sarkar FH, et al.: Mechanisms of curcumin-and EGF-receptor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer 55, 185-194, 2006.
83. Patel BB, Sengupta R, Qazi S, Vachhani H, Yu Y, et al.: Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. Int J Cancer 122, 267-273, 2008.
84. Lao CD, Tt M, Ruffin M, Normolle D, Heath DD, et al.: Dose escalation of a curcuminoid formulation, BMC Complement. Altern Med 6, 10, 2006.
85. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895-2900, 2001.
86. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847-6854, 2004.
87. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894-1900, 2001.
88. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, et al.: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120-125, 2005.
89. Dercks W and Creasy L: The significance of stilbene phytoalexins in the Plasmopara vitiocola-grapevine interactions. Physiol Mol Plant Pathol 34, 189-202, 1989.
90. Soleas, GJ, Diamandis EP, et al.: Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30, 91-113, 1997.
91. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, et al.: Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272, 212-217, 2000.
92. Sabolovic N, Humbert AC, Radominska-Pandya A, and Magdalou J: Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells. Biopharm Drug Dispos 27, 181-189, 2006.
93. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr., and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32, 1377-1382, 2004.
94. Kaldas MI, Walle UK, and Walle T: Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 55, 307-312, 2003.
95. de Santi C, Pietrabissa A, Mosca F, and Pacifici GM: Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30, 1047-1054, 2000. (Pubitemid 32099176)
96. Lançon A, Delmas D, Osman H, Thénot JP, Jannin B, et al.: Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun 316, 1132-1137, 2004.
97. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP, et al.: Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 24, 51-55, 1998.
98. Vitrac X, Desmoulière A, Brouillaud B, Krisa S, Deffieux G, et al.: Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72, 2219-2233, 2003.
99. Delmas D, Rébé C, Lacour S, Filomenko R, Athias A, et al.: Resveratrolinduced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 278, 41482-41490, 2003.
100. Park JW, Woo KJ, Lee JT, Lim JH, Lee TJ, et al.: Resveratrol induces pro-apoptotic endoplasmic reticulum stress in human colon cancer cells. Oncol Rep 18, 1269-1273, 2007.
101. Ito T, Akao Y, Tanaka T, Iinuma M, and Nozawa Y: Vaticanol C, a novel resveratrol tetramer, inhibits cell growth through induction of apoptosis in colon cancer cell lines. Biol Pharm Bull 25, 147-148, 2002.
102. Wolter F, Akoglu B, Clausnitzer A, and Stein J: Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131, 2197-2203, 2001.
103. Chowdhury SA, Kishino K, Satoh R, Hashimoto K, Kikuchi H, et al.: Tumor-specificity and apoptosis-inducing activity of stilbenes and flavonoids. Anticancer Res 25, 2055-2063, 2005.
104. Fuggetta MP, Lanzilli G, Tricarico M, Cottarelli A, Falchetti R, et al.: Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. J Exp Clin Cancer Res 25, 189-193, 2006.
105. Schneider Y, Duranton B, Gossé F, Schleiffer R, Seiler N, et al.: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39, 102-107, 2001.
106. Tessitore L, Davit A, Sarotto I, and Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21 (CIP) expression. Carcinogenesis 21, 1619-1622, 2000.
107. Zhou HB, Chen JJ, Wang WX, Cai JT, and Du Q: Anticancer activity of resveratrol on implanted human primary gastric carcinoma cells in nude mice. World J Gastroenterol 11, 280-284, 2005.
108. Sengottuvelan M and Nalini N: Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1, 2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br J Nutr 96, 145-153, 2006.
109. Majumdar AP, Banerjee S, Nautiyal J, Patel BB, Patel V, et al.: Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer 61, 544-553, 2009.
110. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, et al.: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4, 1035-1038, 2006.